Cargando…

Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference

Despite the high costs of treatment of people with kidney disease and associated comorbid conditions, the amount of reliable information available to guide the care of such patients is very limited. Some treatments have been assessed in randomized trials, but most such trials have been too small to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baigent, Colin, Herrington, William G., Coresh, Josef, Landray, Martin J., Levin, Adeera, Perkovic, Vlado, Pfeffer, Marc A., Rossing, Peter, Walsh, Michael, Wanner, Christoph, Wheeler, David C., Winkelmayer, Wolfgang C., McMurray, John J.V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326036/ https://www.ncbi.nlm.nih.gov/pubmed/28709600 http://dx.doi.org/10.1016/j.kint.2017.04.019

Ejemplares similares

Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
por: Turakhia, Mintu P, et al.
Publicado: (2018)

Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
por: Eckardt, Kai-Uwe, et al.
Publicado: (2018)

Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference
por: Ostermann, Marlies, et al.
Publicado: (2020)

Diseases of the Aorta and Kidney Disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference( )
por: Sarafidis, Pantelis, et al.
Publicado: (2021)

Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
por: Flythe, Jennifer E., et al.
Publicado: (2020)

Central and peripheral arterial diseases in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
por: Johansen, Kirsten L., et al.
Publicado: (2021)

Impact of Outcome Adjudication in Kidney Disease Trials: Observations From the Study of Heart and Renal Protection
por: Herrington, William G., et al.
Publicado: (2023)

Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology
por: Waijer, Simke W., et al.
Publicado: (2022)

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)
por: Staplin, Natalie, et al.
Publicado: (2016)

Proceedings From a Canadian Nephrology Forum: Nephrology Is Back
por: Levin, Adeera, et al.
Publicado: (2020)

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection
por: Mafham, Marion M, et al.
Publicado: (2018)

The need for improved uptake of the KDIGO glomerulonephritis guidelines into clinical practice in Canada: a survey of nephrologists
por: Barbour, Sean, et al.
Publicado: (2014)

Adapting Nephrology Training Curriculum in the Era of COVID-19
por: Cunningham, Amanda, et al.
Publicado: (2021)

A National Vision for Quality Improvement in Canadian Nephrology—The Canadian Nephrology Quality Improvement and Implementation Science Collaborative (CN-QUIS): An Opinion Piece
por: More, Keigan M., et al.
Publicado: (2020)

Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP)
por: Haynes, Richard, et al.
Publicado: (2014)

Atherosclerotic Renovascular Disease: A KDIGO (Kidney Disease: Improving Global Outcomes) Controversies Conference
por: Hicks, Caitlin W., et al.
Publicado: (2022)

Establishing a clinical trials network in nephrology: experience of the Australasian Kidney Trials Network
por: Morrish, Alicia T, et al.
Publicado: (2014)

Evidence for the Prevention and Treatment of Stroke in Dialysis Patients
por: Herrington, William, et al.
Publicado: (2015)

KDIGO Board Members
Publicado: (2012)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
por: Storey, Benjamin C., et al.
Publicado: (2018)

Associations between body mass index and the risk of renal events in patients with type 2 diabetes
por: Mohammedi, Kamel, et al.
Publicado: (2018)

Canadian Society of Transplantation and Canadian Society of Nephrology Commentary on the 2017 KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors
por: Lam, Ngan N., et al.
Publicado: (2020)

Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial
por: Waijer, Simke W., et al.
Publicado: (2022)

Chronic hyperkalemia in non-dialysis CKD: controversial issues in nephrology practice
por: De Nicola, Luca, et al.
Publicado: (2018)

Diabetic Kidney Disease– A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)
por: Molitch, Mark E., et al.
Publicado: (2014)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
por: Schlackow, Iryna, et al.
Publicado: (2017)

Korean Society of Nephrology 2022 Recommendations on controversial issues in diagnosis and management of hyponatremia
por: Lee, Yeonhee, et al.
Publicado: (2022)

Korean Society of Nephrology 2022 Recommendations on controversial issues in diagnosis and management of hyponatremia
por: Lee, Yeonhee, et al.
Publicado: (2022)

Korean Society of Nephrology 2022 Recommendations on Controversial Issues in Diagnosis and Management of Hyponatremia
por: Lee, Yeonhee, et al.
Publicado: (2022)

Korean Society of Nephrology 2022 recommendations on controversial issues in diagnosis and management of hyponatremia
por: Lee, Yeonhee, et al.
Publicado: (2022)

Recovery from AKI by KDIGO criteria
por: Schrijvers, D, et al.
Publicado: (2014)

Pre-ESKD Nephrology Care and Employment at the Start of Dialysis
por: Awan, Ahmed A., et al.
Publicado: (2020)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
por: Herrington, William G, et al.
Publicado: (2018)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
por: Herrington, William G, et al.
Publicado: (2019)

Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference
por: Levey, Andrew S., et al.
Publicado: (2020)

Nomenclature for Kidney Function and Disease: Executive Summary and Glossary From a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference
por: Levey, Andrew S., et al.
Publicado: (2020)

Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference
por: Levey, Andrew S., et al.
Publicado: (2020)

Nomenclature for Kidney Function and Disease: Executive Summary and Glossary From a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference
por: Levey, Andrew S., et al.
Publicado: (2020)

Nomenclature for kidney function and disease: executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference
por: Levey, Andrew S., et al.
Publicado: (2020)

Nomenclature for kidney function and disease: Executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference
por: Levey, Andrew S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rs02cv97egbansa4ljv2016i4c